Nurix Therapeutics reported a net margin of -990.10% for the quarter ended May 2026. These financial ratios cover 28 quarters of results from Aug 2019 through May 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Aug2019 | Nov2019 | Feb2020 | May2020 | Aug2020 | Nov2020 | Feb2021 | May2021 | Aug2021 | Nov2021 | Feb2022 | May2022 | Aug2022 | Nov2022 | Feb2023 | May2023 | Aug2023 | Nov2023 | Feb2024 | May2024 | Aug2024 | Nov2024 | Feb2025 | May2025 | Aug2025 | Nov2025 | Feb2026 | May2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||||
| EBT Margin | -282.46% | -509.17% | -442.09% | -397.14% | -423.58% | -688.74% | -321.11% | -79.14% | -200.26% | -276.77% | -249.79% | -367.65% | -388.26% | -440.69% | -305.38% | -96.93% | -1,094.77% | -576.13% | -1,394.34% | -993.10% | ||||||||
| EBIT Margin | -282.84% | -513.16% | -444.28% | -399.89% | -432.93% | -717.82% | -338.60% | -87.25% | -216.67% | -299.06% | -272.65% | -401.42% | -433.83% | -486.73% | -340.67% | -109.68% | -1,157.65% | -612.03% | -1,479.45% | -1,041.73% | ||||||||
| EBITDA Margin | -282.84% | -513.16% | -444.28% | -399.89% | -432.93% | -717.82% | -338.60% | -87.25% | -216.67% | -299.06% | -272.65% | -401.42% | -433.83% | -486.73% | -340.67% | -109.68% | -1,157.65% | -612.03% | -1,479.45% | -1,041.73% | ||||||||
| Operating Margin | -282.84% | -513.16% | -444.28% | -399.89% | -432.93% | -717.82% | -338.60% | -87.25% | -216.67% | -299.06% | -272.65% | -401.42% | -433.83% | -486.73% | -340.67% | -109.68% | -1,157.65% | -612.03% | -1,479.45% | -1,041.73% | ||||||||
| Net Margin | -281.26% | -509.59% | -442.09% | -397.14% | -423.58% | -688.74% | -321.11% | -79.14% | -200.26% | -276.77% | -250.33% | -368.39% | -388.91% | -440.75% | -305.38% | -98.66% | -1,094.77% | -576.13% | -1,394.34% | -990.10% | ||||||||
| FCF Margin | -310.54% | -429.60% | -479.18% | -312.31% | -460.81% | -597.38% | -399.91% | -63.73% | -236.05% | 159.01% | -270.33% | -344.38% | -353.70% | -382.84% | -349.93% | -149.44% | -761.29% | -537.40% | -1,177.46% | -1,082.09% | ||||||||
| Efficiency | ||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 505.53M | 484.92M | 457.25M | 416.01M | 426.82M | 438.05M | 393.46M | 360.39M | 329.41M | 331.90M | 334.14M | 411.85M | 512.32M | 591.47M | 642.19M | 603.30M | 557.01M | 605.30M | 662.13M | 585.84M | ||||||||
| Asset Utilization RatioAsset Util. | 0.06 | 0.06 | 0.08 | 0.09 | 0.09 | 0.09 | 0.11 | 0.17 | 0.21 | 0.23 | 0.24 | 0.15 | 0.11 | 0.09 | 0.09 | 0.15 | 0.15 | 0.14 | 0.11 | 0.06 | ||||||||
| Valuation | ||||||||||||||||||||||||||||
| Price to EarningsP/E | -49.74 | -34.15 | -17.05 | -10.01 | -16.23 | -12.51 | -10.98 | -19.86 | -11.15 | -7.22 | -14.62 | -22.75 | -34.53 | -28.65 | -20.90 | -18.69 | -8.31 | -23.01 | -18.94 | -20.57 | ||||||||
| Price to SalesP/S | 139.90 | 174.04 | 75.39 | 39.75 | 68.73 | 86.17 | 35.27 | 15.71 | 22.33 | 19.99 | 36.59 | 83.83 | 134.29 | 126.28 | 63.83 | 18.44 | 90.95 | 132.57 | 264.12 | 203.66 | ||||||||
| Price to BookP/B | 3.82 | 3.76 | 2.37 | 1.70 | 2.17 | 1.92 | 1.63 | 1.85 | 1.76 | 1.51 | 3.60 | 2.73 | 4.49 | 3.18 | 2.45 | 1.82 | 1.93 | 3.34 | 3.43 | 4.57 | ||||||||
| Enterprise Value | 1,090.38M | 991.51M | 463.30M | 157.18M | 397.16M | 275.32M | 170.26M | 200.85M | 153.43M | 15.12M | 362.85M | 570.48M | 1,242.45M | 1,067.92M | 628.15M | 326.71M | 289.16M | 1,207.02M | 1,110.56M | 1,398.21M | ||||||||
| EV to EBIT | -37.60 | -26.12 | -10.84 | -3.44 | -8.50 | -5.65 | -3.96 | -7.50 | -3.83 | -0.33 | -8.02 | -11.75 | -22.75 | -16.52 | -9.99 | -6.76 | -3.16 | -14.53 | -12.01 | -14.84 | ||||||||
| EV to EBITDA | -37.60 | -26.12 | -10.84 | -3.44 | -8.50 | -5.65 | -3.96 | -7.50 | -3.83 | -0.33 | -8.02 | -11.75 | -22.75 | -16.52 | -9.99 | -6.76 | -3.16 | -14.53 | -12.01 | -14.84 | ||||||||
| Market Capitalization | 1,434.28M | 1,287.23M | 725.28M | 454.45M | 741.63M | 584.46M | 447.40M | 482.03M | 412.28M | 303.03M | 606.84M | 1,013.62M | 1,690.50M | 1,677.50M | 1,177.83M | 812.49M | 717.99M | 1,799.96M | 1,651.30M | 1,841.74M | ||||||||
| Price to FCFP/FCF | -45.05 | -40.51 | -15.73 | -12.73 | -14.91 | -14.42 | -8.82 | -24.66 | -9.46 | 12.57 | -13.53 | -24.34 | -37.97 | -32.99 | -18.24 | -12.34 | -11.95 | -24.67 | -22.43 | -18.82 | ||||||||
| EV to FCF | -34.25 | -31.21 | -10.05 | -4.40 | -7.99 | -6.79 | -3.36 | -10.27 | -3.52 | 0.63 | -8.09 | -13.70 | -27.91 | -21.00 | -9.73 | -4.96 | -4.81 | -16.54 | -15.09 | -14.29 | ||||||||
| EV to CFO | -36.38 | -32.08 | -10.87 | -4.78 | -8.58 | -7.25 | -3.51 | -10.88 | -3.73 | 0.57 | -8.65 | -14.37 | -29.46 | -21.91 | -10.28 | -5.17 | -5.04 | -17.79 | -15.44 | -14.48 | ||||||||
| Return Ratios | ||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -282.84% | -513.16% | -444.28% | -399.89% | -432.93% | -717.82% | -338.60% | -87.25% | -216.67% | -299.06% | -272.65% | -401.42% | -433.83% | -486.73% | -340.67% | -109.68% | -1,157.65% | -612.03% | -1,479.45% | -1,041.73% | ||||||||
| Return on Capital Employed [ROCE]ROCE | -21.97% | -28.16% | -34.79% | -45.26% | -48.18% | -50.05% | -56.02% | -57.31% | -59.13% | -63.31% | -63.82% | -54.10% | -45.47% | -42.98% | -41.77% | -43.67% | -56.30% | -55.06% | -55.32% | -70.29% | ||||||||
| Return on Assets [ROA]ROA | -19.66% | -24.16% | -29.62% | -37.13% | -40.14% | -41.17% | -45.38% | -43.69% | -45.14% | -43.37% | -43.32% | -40.06% | -34.54% | -32.73% | -32.45% | -34.36% | -43.95% | -43.69% | -44.60% | -58.27% |